Understanding The RTF Letter
By Hugh Donovan, Managing Expert, Advarra Clinical Center of Excellence
The development of new treatments, both drugs and biologics, is a long and arduous process, which can take many years. After the preclinical and clinical programs are successfully completed, the company makes a submission to the U.S. Food & Drug Administration (FDA). The subsequent FDA review, if everything has been done correctly, and the efficacy and safety data are supportive, can be completed within six to twelve months. Read about the two major obstacles to getting approval and market authorization.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.
Subscribe to ECM Connection
X
Subscribe to ECM Connection
Advarra
This website uses cookies to ensure you get the best experience on our website. Learn more